Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/ejdHCfbwocfakrApgOJd

February 1, 2013
BIO has teamed up with FedEx to offer member companies discounts of up to 35% off select FedEx Express, FedEx Ground and FedEx Home Delivery services through the BIO Business Solutions cost-savings program. Learn more.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.

  Today's Top Story 
 
  • 2012 was good, but not great, for biotech VC
    Upfront deal values for venture capital-backed biotech mergers and acquisitions totaled about $3.5 billion last year, which is lower than in 2011 but better than 2008 to 2010, according to data from HBM Partners. Total annual VC-backed private acquisitions have held steady since 2005. The time period from founding to trade sale appears to have risen from about five years in 2005 to nine years in 2012, notes Atlas Venture partner Bruce Booth. Forbes (1/30) LinkedInFacebookTwitterEmail this Story
The New You Starts Here.
Designed for busy healthcare professionals, FIU's online Healthcare MBA is transformative. Graduates emerge ready for a leadership role in healthcare, with a clear vision of how to lead collaboratively and advance the business of healthcare. Classes begin Fall 2015. Start here.

  Health Care & Policy 
 
  • Combo-drug-makers petition FDA on exclusivity period
    Ferring Pharmaceuticals and Gilead Sciences have petitioned the FDA to change how market exclusivity is granted for combination drugs. The agency grants five years' exclusivity if all active compounds in a combination drug are new and three years' exclusivity otherwise. The drugmakers say combination drugs are the same as new drugs and should be treated accordingly. Pharmalot.com/Pharma Blog (1/31) LinkedInFacebookTwitterEmail this Story
  • Orphan drug applications skyrocket as Big Pharma carves out niche
    Rare diseases are attracting renewed interest as multinational drugmakers seek to take advantage of easier approval pathways and high prices for orphan drugs. Firms including Sanofi, Pfizer and GlaxoSmithKlein are working on or have already secured approval for drugs that treat rare conditions. The progress in understanding the molecular base for these diseases has also spurred drugmakers' interest. The Wall Street Journal (1/30) LinkedInFacebookTwitterEmail this Story
  • Companion diagnostics change cancer drug development
    Qiagen filed its application for FDA approval of a test for epidermal growth factor receptor in lung tumors simultaneously with Boehringer Ingelheim's request for approval of a drug that targets the gene mutation. Diagnostic tests help clinicians determine whether drugs that target specific gene mutations will work in individual patients, but insurers hesitate to reimburse diagnostics in the absence of proof that they improve drug efficacy. When tests are developed and approved in tandem with drugs, reimbursement is more likely, says Qiagen’s Stephen Little. Xconomy/Boston (1/31) LinkedInFacebookTwitterEmail this Story
Don't lose access to your customer's facility. We can help.
Rep-Clear: Watermark's Solution for ensuring access to your customers. Rep-Clear includes our proprietary platform for tracking all items associated with a Rep and our professional support staff to provide individual service, ensuring all items are up to date and access to a facility is not lost. View common rep excuses.

  Company & Financial News 
Is Pricing Low Your Strategy to Success? Think again.
Pricing is the heart of a business. It affects everything you do and is affected by everything you do. Economists talk of supply and demand as key factors behind pricing—successful entrepreneurs manipulate demand by making their products more desirable. These six steps will help you determine the right price for your product or service, read the article and learn how to get pricing right.

  Food & Agriculture 
 
  • Biotech crops drive up Burkina Faso's cotton production, producers said
    Burkina Faso's cotton output surged by 57.5% for the year ending in January due to increased use of biotech crops, according to the Burkina National Cotton Producers' Union. Burkina Faso cleared Monsanto's biotech cotton in 2008, making it one of the first African countries to do so. "Genetically modified cotton production is experiencing growth every year," UNPCB president Karim Traore said. Reuters (1/31) LinkedInFacebookTwitterEmail this Story
Clinical Trial Data Transparency Forum: Expert insights
Hear industry and academic thought leaders - from Duke Clinical Research Institute, GlaxoSmithKline, Eli Lilly and more - share valuable insight on their clinical trial data transparency and sharing initiatives. This video covers a number of key perspectives and trends.

  Industrial & Environmental 
  • Court ruling does not weaken RFS, legal experts say
    The recent court ruling that vacated the cellulosic portion of the Renewable Fuel Standard's 2012 volumetric targets will not have a major impact on the standard, write Jody M. Endres and A. Bryan Endres, law professors at University of Illinois. Although the court found fault in the Environmental Protection Agency's approach of favoring overestimation of output volumes, "the RFS itself, and EPA's general methodology of establishing both advanced and cellulosic biofuel projections, both survived" the legal challenge, they state. Farmdoc Daily (University of Illinois) (1/30) LinkedInFacebookTwitterEmail this Story
The Buzz(CORPORATE ANNOUNCEMENTS)

Interested in learning more about advertising in BIO SmartBrief? Contact Meryl Harold at (202) 407-7828 or mharold@smartbrief.com. 

  News from BIO 
  • Are you taking full advantage of your membership?
    BIO's cost-savings program, BIO Business Solutions, is helping 2,700 companies nationwide save on the cost of essential products and services. Members of BIO and 43 state and regional biotech associations are eligible to receive preferential pricing and other benefits at no additional cost beyond their membership dues. VWR International, FedEx, Office Depot and Business Wire are just a few of the industry leading providers that offer special pricing through this members-only program. Learn more or enroll here. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

  SmartQuote 
Never confuse a single defeat with a final defeat."
--F. Scott Fitzgerald,
American writer


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
     
Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Account Director:  Meryl Harold (202) 407-7828
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2013 SmartBrief, Inc.® Legal Information